Can a low dose of ketamine change how people with treatment-resistant depression remember their lives, deal with emotions, and make decisions?

This parallel-arm placebo-controlled experimental medicine study (n=60) aims to investigate whether a low dose of ketamine can alter autobiographical memory, emotional processing, and decision-making in individuals with treatment-resistant depression (TRD).

The study, conducted by the Department of Psychiatry, University of Oxford, UK, investigates the effects of ketamine, a licensed drug impacting glutamate levels in the brain. Glutamate, involved in memory, prompts an examination of ketamine’s effects on memory, emotional understanding, reward learning, and motivation in TRD.

Participants, adults with TRD unresponsive to standard antidepressants, undergo health screening, questionnaires, computer tasks, and pre-and post-ketamine/placebo MRI scans. Risks include MRI scans, ketamine administration, and questionnaire completion.

Funded by the Medical Research Council (UK), Janssen Pharmaceutical (USA), and Wellcome Trust (UK), the study has ethics approval and is scheduled from October 2017 to March 2024.

Recruitment occurred from April 20, 2022, to February 28, 2024, at the University of Oxford, UK. Exclusions apply to participants with specific psychiatric or medical conditions, substance use disorders, or MRI contraindications.

Publication is anticipated by September 30, 2024, with individual participant data available upon request.

Status Active, not recruiting
Results Published Yes
Start date 01 October 2017
End date 30 March 2024
Phase Not Applicable
Design Open
Type Interventional
Generation First
Participants 60
Sex All
Age 20- 60
Therapy No

Trial Details

Clinical depression often involves a pessimistic view of things which have happened in the past and an impairment in the ability to experience pleasure or look forward to things. A licensed drug called ketamine affects the levels of glutamate, a chemical messenger in the brain, and has been used as a treatment, particularly for depression which hasn’t got better with other types of medication. Glutamate plays a role in learning and memory so we are interested in understanding how ketamine can affect how people with depression remember past negative and positive memories. This project will help us understand what is the role of glutamate in depression and will expand our understanding of how ketamine can influence memory, the way people understand emotions and learn from rewards and punishments, and motivation.

NCT Number ISRCTN68107842

Sponsors & Collaborators

Janssen-Cilag
This company doesn't have a full profile yet, it is linked to a clinical trial.

University of Oxford
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.